CN Patent

CN101588797A — 带有最小化副作用包括减轻肝毒性的对乙酰氨基酚组合物

Assigned to Individual · Expires 2009-11-25 · 16y expired

What this patent protects

本发明公开了固体片剂或凝胶胶囊，其包含对乙酰氨基酚和用于减轻对乙酰氨基酚肝毒性的巯基－2－氨烷基羧酸，其为谷胱甘肽生成促进剂。优选组合物可含有阿片剂、抗组胺药、止吐药和镇静剂中的至少一种。

USPTO Abstract

本发明公开了固体片剂或凝胶胶囊，其包含对乙酰氨基酚和用于减轻对乙酰氨基酚肝毒性的巯基－2－氨烷基羧酸，其为谷胱甘肽生成促进剂。优选组合物可含有阿片剂、抗组胺药、止吐药和镇静剂中的至少一种。

Drugs covered by this patent

diclofenac-potassium (DICLOFENAC POTASSIUM)

Patent Metadata

Patent number: CN101588797A
Jurisdiction: CN
Classification: —
Expires: 2009-11-25
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.